Gerresheimer faces delisting, technical default risk, and a BaFin accounting probe, forcing asset sales and freezing its corporate calendar as it fights for survival.
The removal of Gerresheimer from Germany’s SDAX index, confirmed by STOXX to take effect April 10, is merely the most visible symptom of a deepening corporate crisis. The packaging group’s failure to publish its audited financial statements for 2024/25 by a March 31 deadline triggered the automatic delisting. Behind the administrative failure lies a serious accounting scandal that now threatens the company’s very financing.
Gerresheimer is currently negotiating with its lenders to avoid a technical default, having breached contractual reporting obligations. The entire corporate calendar is frozen: the audited 2025 report is postponed until June 2026, while the Q1 2026 report and the annual general meeting are on indefinite hold. To alleviate pressure on its credit lines, management has initiated a major asset sale. The US pharmaceutical packaging unit Centor, carried on the books at 292 million euros, is being marketed for sale via Morgan Stanley. Concurrently, the company will shutter its Chicago Heights plant by the end of 2026.
The root cause of the delay is an investigation by German financial watchdog BaFin into alleged accounting errors related to “bill-and-hold” agreements. The situation has ensnared the company’s auditor, KPMG. The oversight body APAS has now launched a probe into KPMG for issuing an unqualified audit opinion on the 2024 accounts despite the alleged systematic flaws. Notably, KPMG had only just replaced previous auditor Deloitte in 2024 before certifying the faulty statements. A separate firm, Grant Thornton, is now conducting a special audit for both 2024 and 2025.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Legal risks are multiplying. Shareholder association DSW is examining damage claims against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner, with scrutiny also extending to the supervisory board. DSW’s chief executive, Marc Tüngler, indicated that a litigation financier could step in if clear claims are established.
Despite the turmoil, the stock showed a muted reaction to the SDAX news. It currently trades at 18.19 euros, far below its 200-day moving average of 30.40 euros. The share price has fallen approximately 34% since the start of the year, with a 67% drop over the past twelve months, shrinking the market capitalization to about 607 million euros. This depressed level has attracted some institutional buyers; investors CastleKnight and Deka have used the weakness to establish new positions, betting against still-active short sellers.
The company’s financial outlook is clouded by significant non-cash impairments. For the 2025 fiscal year, Gerresheimer expects write-downs of 220 to 240 million euros, primarily from technology projects at Sensile Medical AG and US assets. Its revenue forecast of 2.3 to 2.4 billion euros for 2026 is explicitly conditional on securing its credit facilities and the outcome of the BaFin probe.
All potential paths to recovery converge on a single month. June 2026 is the critical milestone when Gerresheimer must finally present its audited financial statements. Success hinges on simultaneously resolving the BaFin allegations and proving its financing is secure. Failure on either front would maintain a blockade on corporate activity, including a potential takeover bid. Reuters reported that US rival Silgan Holdings had considered an offer of 41 euros per share, a scenario that remains frozen. The subsequent half-year report is scheduled for July 14, 2026, offering the next glimpse into whether stability can be restored.
Ad
Gerresheimer Stock: New Analysis – 9 April
Fresh Gerresheimer information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Leave a comment